INTRODUCTION
Scattered through the exocrine pancreas, the islets of Langerhans are highly organized clusters of endocrine cells comprised of four distinct cell types: the glucagonsecreting alpha-cells, the insulin-secreting beta-cells, the somatostatin-secreting deltacells, and the pancreatic polypeptide-secreting PP cells. Because of the essential role of the islet hormones in energy metabolism, defects in the development, maintenance or function of the endocrine pancreas have serious consequences, including diabetes mellitus.
The pancreas forms from the endoderm in the region of the foregut/midgut junction and is first visible in mice at embryonic day 9.5 (e9.5) (1) . The first endocrine cells of the pancreas appear at around e9.5 in the dorsal pancreatic bud. These cells express glucagon; a few insulin-expressing cells appear approximately a day later. At approximately e13-14, the pancreas undergoes a distinct change termed the secondary transition, characterized by the appearance of ductal cells, exocrine cells, and delta cells, and a rapid expansion of the insulin-expressing cells. The endocrine cells found in the pancreas prior to the secondary transition have clear differences from mature islet cells, and may result from developmental pathways that are distinct from those that produce the more mature endocrine cells that arise following the secondary transition (2-6). By e18, the first PP-expressing cells appear, and the endocrine cells organize into distinct islets with the beta-cells forming the central core. Around the same time, beta-cell neogenesis declines; but the simultaneous onset of beta-cell replication continues to expand the betacell population and enlarge the forming islets (7).
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This process of endocrine cell determination and differentiation depends on the proper sequential actions of multiple transcription factors (8). The basic helix-loop-helix transcription factor neurogenin3 initiates endocrine differentiation, and is both necessary and sufficient to drive the differentiation of the undifferentiated pancreatic epithelial cells to an endocrine fate (9-13). Neurogenin3 expression is transient, but activates the expression of the factors that complete endocrine differentiation, including the basic helix-loop-helix transcription factor neuroD1, and the homeodomain transcription factors pax4 and nkx2.2 (14-18), all three of which are required for proper beta-cell differentiation and islet development; (19-21). Nkx2.2 in turn activates expression of the homeodomain transcription factor nkx6.1, which is also required for normal beta-cell differentiation (5; 19). In addition, neurogenin3 activates, either directly or indirectly, the expression of several other homeodomain transcription factors that play a role in islet development (12; 14; 22). Interestingly, with the exception of nkx2.2, none of these factors downstream of neurogenin3 are required for the differentiation of the endocrine cells that appear prior to the secondary transition.
In order to extend our understanding of the transcriptional cascade controlling the differentiation of the endocrine pancreas, we examined the role of members of the Sry/HMG box (Sox) family of transcription factors. Members of the Sox family contribute to the development of a variety of tissues (23; 24), and several Sox factors have been detected in the developing pancreas (25-30). We found that sox4 was the most highly expressed Sox gene in the endocrine pancreas in the mouse, and therefore examined its role in the development of the endocrine pancreas.
METHODS

Mice
Mice were housed on a 12hr light dark cycle with controlled climate, according to the regulations of the University of California, San Francisco. Mid-day of the day on which the vaginal plug was discovered was considered e0.5 in the timing of embryo collection. CD1 mice were obtained from Charles River Laboratories and used for all studies on normal mice. The sox4 mutant mice have been described previously (31).
The sox2 mutant mice were generated by disrupting the sox2 locus with the bgeo gene by homologous recombination in ES cells (32).
Glucose tolerance tests
6 month old mice were fasted for 12 hours, then injected intraperitoneally with glucose at 1mg/kg body weight. Blood was sampled from the tail vein prior to injection of glucose and at the time points indicated after injection up to 180 minutes. Blood glucose was measured using a Glucometer 2 meter (Bayer).
RT-PCR
Total RNA was isolated with the RNAqueous kit (Ambion) from the indicated cells and tissues. First-strand cDNA was prepared from 1-3ug of total RNA with the Invitrogen SuperScript first strand cDNA synthesis kit and oligo dT primers.
First-strand cDNA served as a template for PCR amplification as previously described (10) using the following degenerate primers derived from conserved amino 6 acid sequences within the HMG DNA-binding domain of all Sox family members: 5'primer: cagctctagaCCIATGAAYGCITTYATGGTIGG, 3'primer :
ggacctcgagGICKRTAYTTRTARTCIGG. PCR products were cloned into the pBlueScript (KS+) vector (Stratagene) and sequenced.
For TaqMan real time PCR quantification, 30ng of cDNA were used as a template. All primer/probe sets for TaqMan RT-PCR were validated with a standard curve by using serial cDNA dilutions. Assays for sox2 were performed with ABI mSox2
Assay-on-demand and ABI TaqMan Universal PCR Master Mix. All other assays used 200uM dNTP, 5.5mM MgCl 2 , 500nM forward/reverse primers and 100nM probe in 50ul
for 40 cycles with the ABI TaqMan Gold Kit. Quantification was performed on an Applied Biosystems Prism 7700 sequence detection system. Results are reported relative to the level of mouse Histone3.3A mRNA, which was used as an internal control for cDNA quantity and quality in all assays. Sequences of all primers and probes are available on request.
Pancreatic bud culture
The dorsal and ventral pancreatic primordia and attached stomach and foregut were dissected from e11.5 embryos, and placed on Matrigel matrix without phenol red (Becton, Dickinson and Company) contained within Millicell culture plate inserts (Millipore). The explants were incubated in 50% DME H-16, supplemented with nonessential amino acids, 1.4g/l glucose, 0.11g/l sodium pyruvate, 0.365g/l linoleic acid, After 8 days in culture, the fetal pancreas explants were photographed, fixed in 2.5% PFA for 10 minutes at room temperature, dehydrated through graded ethanols, embedded in paraffin (paraplast) and sectioned at 5mm.
Immunohistochemical and immunofluorescence assays.
Immunohistochemical and immunofluorescence analyses were performed on paraffin sections as described previously (33). For b-galactosidase staining, embryos harvested on the dates indicated embryos were fixed for 20-45 min on ice in 2% paraformaldehyde (PFA) and 0.1% glutaraldehyde. Tissues were incubated overnight at 37° with X-gal (1 mg/ml) as previously described (34). Gross embryos and dissected pancreases were visualized using a Leica dissecting microscope and imaged with a Spot RT digital camera and Openlab software. The tissues were fixed again in 4% paraformaldehyde, paraffin embedded, and sectioned at 5 mm.
Primary antisera employed in the assays were diluted in 5% goat serum/PBS at the following dilutions: Guinea pig anti-insulin (Linco), 1:4,000; mouse anti-glucagon All slides were visualized with a Zeiss Axioskop II microscope and imaged with a Hamamatsu ORCA100 digital camera and Openlab software.
In situ hybridization
For RNA in situ hybridization analysis of paraffin sections (5µm), adult mouse pancreas was processed, sectioned and hybridized with digoxigenin-labeled riboprobes as previously described (10). Digoxigenin-labeled sense and antisense riboprobes were detected with alkaline phosphatase-coupled anti-digoxigenin antibodies using BM purple (Boehringer Mannheim) as color substrate. The sox4 sense and anti-sense riboprobes were transcribed in vitro from a fragment consisting of bp 1427 to 1776 of mouse sox4
(accession number X70298). The sense probe gave no significant signal on adult mouse pancreas.
Microarray gene expression analysis
Slides carrying approximately 22,000 mouse cDNAs were generated by the Pancreatic buds were extracted from sox4 mutant mice at e12.5. Buds from homozygous mutants and wild-type embryos were pooled separately and total RNA was isolated using the RNeasy Mini Kit (Qiagen) and treated with RNase-free DNase according to the manufacturer's protocol. 2ug of total RNA were amplified with the MessageAmp aRNA Kit (Ambion). 5ug of amplified RNA from sox4 -/-and sox4 +/+ embryos were labeled with Cy3 and Cy5 respectively as previously described (14).
Labeled samples were hybridized and washed as previously described (36). Microarrays were scanned with an Axon 400B scanner (Axon Instruments) and the data were analyzed using microarray analysis software Genepix v.4 (Axon Instruments) and the NOMAD microarray database system (http://ucsf-nomad.sourceforge.net/). Two hybridizations were performed from amplified RNA from each of three independent amplifications and used to calculate the mean fold difference and standard error of the mean shown in Table   1 .
RESULTS
Expression of Sox family members in the pancreas.
To survey the Sox genes expressed in the pancreas, we designed degenerate oligonucleotides that recognized all known mammalian Sox family members, and used them to amplify cDNA from mouse fetal pancreas and adult islets by PCR (26). Of 50 independent PCR products from adult islets, 69 percent encoded Sox4; and the remainder encoded Sox10, 11, 12 and 15. From cDNA harvested from fetal pancreas at embryonic day 15.5 (e15.5), 25 percent of sequenced products encoded Sox4; Sox9, 11 and 15 were highly represented (> 10%); and Sox5, 7, 8, 10, 12, 13 and 21 were also present. We also detected cDNA encoding Sox2 from fetal pancreas at e10.5. All but Sox2 and 12 have been reported previously in the pancreas (25-30).
To assess the temporal expression pattern of selected Sox mRNAs, we used
TaqMan real-time RT-PCR, and included Neurogenin3 (Ngn3) for comparison ( Fig. 1 ).
The mRNAs encoding Sox2, 11, and 12 were present at e10.5 (Fig. 1A , B and C), but rapidly declined prior to the secondary transition at e13, although modest levels of sox12 mRNA persisted in adult islets. The expression levels of mRNA encoding Sox2 and 11
were significantly lower than the other mRNAs tested (Fig. 1H ). Levels of mRNA encoding Sox4 peaked during the secondary transition, and persisted at high levels in adult islets (Fig. 1D ). The expression pattern of mRNA encoding Sox9 most closely mirrored that of Ngn3, with a marked peak during the secondary transition (Fig. 1E ). The expression level of the mRNA encoding Sox13 varied the least over the period tested, and along with Sox4 remained at high levels in adult islets (Fig. 1F ).
These RT-PCR data cannot establish which cells within the pancreas express each mRNA. To assess the spatial expression pattern of sox2 within the pancreas, we examined mouse embryos heterozygous for a sox2 allele disrupted by the chimeric bgeo gene encoding a beta-galactosidase/neomycin fusion protein. Cells expressing the sox2 gene were identified with the beta-galactosidase substrate X-gal, and the pancreas was identified by immunohistochemical staining for the Pdx1 homeodomain transcription factor ( Fig. 2) . At e9.5, the foregut, especially the developing stomach, stained strongly for beta-galactosidase activity, and the proximal midgut stained more weakly ( Fig. 2A ), but the dorsal pancreatic bud did not express beta-galactosidase ( Fig. 2B ). At e10.5, staining in the foregut was reduced; and by e16.5 there was no apparent staining of gut epithelium. There was no staining in the pancreas at either e10.5 or e16.5 (data not shown). Therefore, in the early pancreatic bud, when sox2 mRNA was detected in samples from the developing pancreas ( 
Islet development in sox4 null embryos.
To test the role of Sox4 in pancreatic development, we examined the development of the pancreas in mice with a targeted disruption of the sox4 gene (31). Adult heterozygous sox4 mutant mice appeared normal, with no difference in weight from their wild-type littermates. By intraperitoneal glucose tolerance test at age 6 months, the heterozygotes tended to have higher glucose levels than their wild-type littermates despite weighing less (Fig. 4 ) (p=0.06 at 30 minutes by two-tailed Student's T test).
We examined the developing pancreas in these mice at stages up to e12.5 and found no morphological differences in the pancreas between homozygous null animals and wild type littermates. Assessment of insulin, glucagon and Pdx1 expression by immunohistochemistry also revealed no differences between sox4 -/-, sox4 +/-and wildtype littermates at this age (data not shown). To test for changes in gene expression we labeled cDNA from e12.5 pancreas from sox4-/-and their wildtype littermates and compared the expression patterns by hybridization on microarrays containing approximately 22,000 mouse cDNAs (Table 1) . Although by immunohistochemistry we detected no difference in staining for insulin protein at e12.5, the microarray studies detected a consistent reduction in both insulin1 and insulin2 mRNA levels in the mutant pancreases. Among other mRNA reduced in the mutants, messages encoding the homeodomain transcription factor Nkx6.1 and antioxidant enzymes (peroxiredoxin 2 and glutathione peroxidase 1) were also significantly reduced in the mutants. Interestingly, the mRNAs encoding Sox11 and both islet bHLH proteins (neurogenin3 and neuroD1)
were increased in the mutants. The complete gene expression data set has been deposited in NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number GSE2539.
Unfortunately, homozygous sox4 mutant embryos do not survive beyond e14
because of cardiac defects (37). At e13.5, however, the pancreas has just reached the secondary transition, and very few insulin-expressing cells can be detected before that time. Therefore, we cultured explants of pancreas from e11.5 embryos for 8 days under
conditions that allowed islet development to continue ex vivo (38) ( The few endocrine cells present showed some tendency to cluster in the Sox4 -/-explants but did not generate well-formed islets with a core of beta cells surrounded by alpha cells, whereas classic islets formed in explants from wild type and Sox4+/-embryos. Insulin and glucagon expressing cells in the explants were quantified, and Sox4 -/-animals were found to have significantly reduced numbers of insulin expressing cells (Fig. 5I) .
Assessment of the frequency of replication and apoptosis of the insulin-positive cells by staining for KI67 and activated caspase 3 respectively demonstrated no change in the cultured Sox4 -/-pancreatic explants compared to control explants (data not shown). approximately 100 hours, so it may take a long time after the initial differentiation of a beta-cell before enough insulin accrues to allow its detection with anti-insulin antibodies.
Therefore, although there is no reduction in insulin-expressing cells in Sox4 mutant embryos at e12.5, the number of cells that have initiated both nkx6.1 and insulin gene transcription and would normally be detectable a day later may already be reduced.
Consistent with this interpretation, we also saw a reduction in transcripts for both insulin1
and insulin2 at e12.5 in the Sox4 mutant embryos (Table 1) . These data are consistent with the assumption that the morphologic and immunohistologic changes that characterize the secondary transition in the pancreas at e13 are preceded by changes in the gene expression program a day earlier.
Interestingly, we now know of several transcription factors that contribute to endocrine cell differentiation after, but not before, the secondary transition, including the homeodomain transcription factors Pdx1, Pax4, and Nkx6.1 (5; 21; 57-59). In embryos lacking any of these three factors, the early endocrine cells differentiate apparently "This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes (http://diabetes.diabetesjournals.org). The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisherauthenticated version is available online at http://diabetes.diabetesjournals.org/."
